A Study of Sepiapterin in Participants With Phenylketonuria (PKU) (EPIPHENY)

PTC Therapeutics

Status and phase

Enrolling

Phase 3

Conditions

Phenylketonuria

Treatments

Drug: Sepiapterin

Study type

Interventional

Funder types

Industry

Identifiers

NCT06302348

PTC923-PKU-401

2024-514435-20-00 (Other Identifier)

Details and patient eligibility

About

The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.

Full description

The study includes 2 parts: Part 1 and 2. Part 1 is an open-label sepiapterin-responsiveness test, and Part 2 is an open-label treatment period.

Enrollment

56 estimated patients

Sex

All

Ages

Under 12 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

For all participants:

Women of childbearing potential must have a negative pregnancy test at screening and agree to abstinence or the use of at least one highly effective form of contraception for the duration of the study, and for up to 90 days after the last dose of the study drug.
Willing to maintain prescribed daily protein/Phe during Screening and Part 1.
Established diagnosis of PKU with hyperphenylalaninemia (HPA) evidenced by at least 1 blood Phe measurement ≥600 micromoles (μmol)/liter (L) as documented in the medical history.
For participants ≥1 month of age at Screening: A minimum of 1 documented blood Phe measurement <480 μmol/L within 1 month prior to Screening.
For participants ≥1 month of age at Screening: Two screening blood Phe concentration values must be in the range ≥120 to ≤480 μmol/L.

For participants <1 month of age at the time of informed consent/assent only:

Blood Phe at newborn screening ≥600 μmol/L.

For participants ≥30 months to <12 years of age:

Baseline FSIQ score ≥80.

Key Exclusion Criteria:

History of allergies or adverse reactions to any of the ingredients or excipients of synthetic tetrahydrobiopterin (BH4) or sepiapterin.
Serious neuropsychiatric illness (for example, major depression) not currently under medical control or other concurrent disease or condition that, in the opinion of the investigator or sponsor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant.
Treatment with BH4 supplementation (sapropterin, KUVAN) within 3 months prior to Screening.
Current participation in another investigational drug study or use of any investigational agent within 30 days prior to Screening.
Confirmed diagnosis of a primary BH4 deficiency as evidenced by biallelic pathogenic mutations in 6-pyruvoyltetrahydropterin synthase, recessive Guanosine-5'-triphosphate (GTP) cyclohydrolase I, sepiapterin reductase, quinoid dihydropteridine reductase, or pterin 4-alphacarbinolamine dehydratase genes.
Any clinically significant laboratory abnormality as determined by the investigator.
Any past medical history of an abnormal physical examination and/or laboratory findings indicative of signs or symptoms of renal disease, including calculated (Bedside Schwartz Equation) glomerular filtration rate (GFR) <60 milliliters (mL)/minute (min)/1.73 square meter (m^2).
Major surgery within 90 days prior to Screening visit.

Note: Other protocol-defined inclusion and exclusion criteria may apply.